Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anacor attracts big pharma investment

This article was originally published in Scrip

Executive Summary

Anacor Pharmaceuticals has raised $50 million after two major pharmaceutical firms joined other investors in an equity financing. GlaxoSmithKline and Schering-Plough joined a host of venture capitalists to advance Anacor's product development. GSK and Schering-Plough will together own less than 20% of Anacor and their investment fulfils obligations related to ongoing collaborations with the company. The proceeds will allow Anacor to develop its five clinical programmes and identify new compounds derived from its boron chemistry platform. Anacor's lead compound is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. The candidate is licensed to Schering-Plough for all indications.

You may also be interested in...



AB Science lists on Euronext after reducing offer size

AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.

Amgen posts strong first-quarter sales but healthcare reform set to bite

Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.

Tracleer drives growth for Actelion

Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel